Personalized chemotherapy reduction for advanced Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a personalized approach to using a blood test (ctDNA) to decide how much chemotherapy you need. If you have advanced Hodgkin lymphoma, this study might let you have less chemo if the blood test shows a strong response early on, potentially reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with classical Hodgkin lymphoma, stage 3 or 4, and have not yet received any systemic treatment (like chemotherapy or immunotherapy) for it.
- Your disease must be measurable (meaning it can be seen on scans or other tests).
- You need to be fit enough to receive at least 6 cycles of a standard chemotherapy combination that includes an anthracycline (a type of chemo).
- Your blood counts and liver/kidney function must be within certain limits, but there are exceptions if low counts are due to the lymphoma itself.
- You cannot have active central nervous system (brain or spinal cord) lymphoma, or other serious medical conditions like severe heart disease, recent heart attack, or need for supplemental oxygen.
- If you are of childbearing potential, you must agree to use effective birth control during treatment and for 120 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy for people with newly diagnosed Hodgkin lymphoma who are too frail for standard treatment. The goal is to find a safer, effective option for patients who are older or have other health issues.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
This study tests whether using a special blood test (ctDNA) to guide targeted therapy can improve outcomes for people with a type of lymphoma called DLBCL. If you qualify, you may receive a standard chemo-immunotherapy regimen (R-CHOP) possibly combined with other drugs, and your treatment plan may be adjusted based on your ctDNA levels.
This trial tests a new treatment where your own immune cells are modified to better attack Hodgkin lymphoma cells. It is for people whose disease has not responded to other therapies.
Hear when a new Advanced Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.